Oliver McAteer
Dec 13, 2019

IPG's MRM, McCann Health to wrangle GSK global creative pharma along with Publicis

Separately, WPP retains GSK's US pharma media business.

IPG's MRM, McCann Health to wrangle GSK global creative pharma along with Publicis

Pharmaceutical giant GlaxoSmithKline has handed its global creative Rx business to IPG and Publicis Groupe, Campaign US has learned. 

The bulk of this business will be wrangled by MRM and McCann Health, as well as other IPG agencies, which now oversee oncology and vaccines—the former being a core focus of investment for GSK, according to people with knowledge of the matter. 

Meanwhile, Publicis Groupe takes on the client's respiratory business. 

The review, which kicked off in September, was handled internally and led by procurement. While the review was run out of London, the majority of GSK’s revenue comes from the U.S. market. The pharma account is believed to make up around two-thirds of its business. 

McCann Health already had a sizeable piece of GSK pharma work.

Both IPG and Publicis Groupe referred comment to the client. GSK has not yet responded to a request for comment. 

Greg Paull, principal at R3 Worldwide consultancy group, said: "Building a strong global healthcare agency business is no easy matter—this is a positive endorsement of the strides McCann has made to really put experts on the map."

News of the pitch conclusions comes a year after GSK awarded its $1.7 billion media business to Publicis Media. 

Publicis created a dedicated agency unit for the account called "platformGSK" which brings together different expertise from across Publicis Media in healthcare, consumer strategy and digital business transformation.

At the time, GSK Consumer Healthcare VP and Global Head of Media Scott Grenz said: "We ran a very thorough and competitive pitch process with strong presentations from all companies, but ultimately Publicis was the best fit for us. We’re excited about the new partnership and the potential of the platformGSK model as we continue to progress our marketing transformation program."

The review, which was handled by ID Comms, came less than three years after GSK awarded its European business to MediaCom, with PHD handling the U.S. media work. Both agencies had retained the accounts in 2015 following a global media review. They first won the business in 2013.

Source:
Campaign US

Related Articles

Just Published

9 hours ago

Agency Report Cards 2024: We grade 25 APAC networks

The grades are in for Campaign Asia's 22nd annual evaluation of APAC agency networks. Subscribe to read our detailed analyses.

10 hours ago

Publicis Groupe acquires influencer agency Captiv8

Captiv8 will join forces with the group's Influential and Epsilon.

10 hours ago

Agency Report Card 2024: EssenceMediacom

In a difficult year underlined by restructuring and turmoil within parent company GroupM, the world’s largest media agency still holds many of the keys to mount a stronger rebound in 2025.

10 hours ago

Disney sets sail: VP Sarah Fox on the brand’s ...

With localised strategy, strong fan engagement, and Disney’s knack for storytelling, Cruise Line will make its maiden voyage in December 2025. Campaign speaks exclusively with VP and regional GM Sarah Fox ahead of Campaign 360 next week.